Cited by 163Cancer Immunotherapy and BiomarkersAdvanced Breast Cancer TherapiesImmunotherapy and Immune Responses

The DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.

Immunomodulation by anticancer cell cycle inhibitors

Open access

Petroni, Giulia, Formenti, Silvia C., Chen-Kiang, Selina, Galluzzi, Lorenzo·2020·Nature Reviews Immunology

DOI 10.1038/s41577-020-0300-yPMC PMC7584736

Open this paper in CoChat — free account

Abstract

Cell cycle proteins that are often dysregulated in malignant cells, such as cyclin-dependent kinase 4 (CDK4) and CDK6, have attracted considerable interest as potential targets for cancer therapy. In this context, multiple inhibitors of CDK4 and CDK6 have been developed, including three small molecules (palbociclib, abemaciclib and ribociclib) that are currently approved for the treatment of patients with breast cancer and are being extensively tested in individuals with other solid and haematological malignancies. Accumulating preclinical and clinical evidence indicates that the anticancer activity of CDK4/CDK6 inhibitors results not only from their ability to block the cell cycle in malignant cells but also from a range of immunostimulatory effects. In this Review, we discuss the ability of anticancer cell cycle inhibitors to modulate various immune functions in support of effective antitumour immunity.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41577-020-0300-y

Cites

159 of 159 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citation
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400
Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway
Sun, L., Wu, J., Du, F., Chen, X., & Chen, Z. J. (2013) · Science · doi:10.1126/science.1232458 · Cited by 4,996
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA.
Bauer, S., Groh, V., Wu, J., Steinle, A., Phillips, J., Lanier, L., & Spies, T. (1999) · Science · doi:10.1126/science.285.5428.727 · Cited by 3,272
Cellular Senescence: Defining a Path Forward
Gorgoulis, V., Adams, P. D., Alimonti, A., Bennett, D. C., Bischof, O., Bishop, C., Campisi, J., Collado, M., Evangelou, K., Ferbeyre, G., et al. (2019) · Cell · doi:10.1016/j.cell.2019.10.005 · Cited by 3,225
CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis
Qian, B.-Z., Li, J., Zhang, H., Kitamura, T., Zhang, J., Campion, L. R., Kaiser, E. A., Snyder, L. A., & Pollard, J. W. (2011) · Nature · doi:10.1038/nature10138 · Cited by 2,874
Innate or adaptive immunity? The example of natural killer cells
Vivier, E., Raulet, D. H., Moretta, A., Caligiuri, M. A., Zitvogel, L., Lanier, L. L., Yokoyama, W. M., & Ugolini, S. (2011) · Science · doi:10.1126/science.1198687 · Cited by 2,824
Dendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2019) · Nature reviews. Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,660
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278
Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals
Polyák, K., Lee, M.-H., Erdjument‐Bromage, H., Koff, A., Roberts, J. M., Tempst, P., & Massagué, J. (1994) · Cell · doi:10.1016/0092-8674(94)90572-x · Cited by 2,118
The Immunological Genome Project: networks of gene expression in immune cells
The Immunological Genome Project Consortium, Heng, T. S. P., Painter, M. W., Elpek, K., Lukacs-Kornek, V., Mauermann, N., Turley, S. J., Koller, D., Kim, F. S., Wagers, A. J., et al. (2008) · Nature Immunology · doi:10.1038/ni1008-1091 · Cited by 1,864
TGFβ drives immune evasion in genetically reconstituted colon cancer metastasis
Tauriello, D. V. F., Palomo-Ponce, S., Stork, D., Berenguer-Llergo, A., Badia-Ramentol, J., Iglesias, M., Sevillano, M., Ibiza, S., Cañellas, A., Hernando-Momblona, X., et al. (2018) · Nature · doi:10.1038/nature25492 · Cited by 1,851
Chemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801
Cyclin-dependent kinases
Malumbres, M. (2014) · Genome biology · doi:10.1186/gb4184 · Cited by 1,730
Senescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621
CDK4/6 inhibition triggers anti-tumour immunity
Goel, S., DeCristo, M. J., Watt, A. C., BrinJones, H., Sceneay, J., Li, B. B., Khan, N., Ubellacker, J. M., Xie, S., Metzger-Filho, O., et al. (2017) · Nature · doi:10.1038/nature23465 · Cited by 1,513
A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
Jerby-Arnon, L., Shah, P., Cuoco, M. S., Rodman, C., Su, M.-J., Melms, J. C., Leeson, R., Kanodia, A., Mei, S., Lin, J.-R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.09.006 · Cited by 1,429
Autophagy maintains stemness by preventing senescence
García-Prat, L., Martínez-Vicente, M., Perdiguero, E., Ortet, L., Rodríguez-Ubreva, J., Rebollo, E., Ruiz-Bonilla, V., Gutarra, S., Ballestar, E., Serrano, A. L., et al. (2016) · Nature · doi:10.1038/nature16187 · Cited by 1,355
From chemotherapy to biological therapy: A review of novel concepts to reduce the side effects of systemic cancer treatment (Review)
Schirrmacher, V. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4661 · Cited by 1,342
Cellular senescence promotes adverse effects of chemotherapy and cancer relapse
Demaria, M., O'Leary, M. N., Chang, J., Shao, L., Liu, S., Alimirah, F., Koenig, K., Le, C., Mitin, N., Deal, A. M., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0241 · Cited by 1,338
Type I interferons in anticancer immunity
Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M. J., & Kroemer, G. (2015) · Nature Reviews Immunology · doi:10.1038/nri3845 · Cited by 1,305
Self-citation
Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4
(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts
Fry, D. W., Harvey, P. J., Keller, P. R., Elliott, W. L., Meade, M., Trachet, E., Albassam, M., Zheng, X., Leopold, W. R., Pryer, N. K., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.1427.3.11 · Cited by 1,236
DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts.
Di Leonardo, A., Linke, S. P., Clarkin, K., & Wahl, G. M. (1994) · Genes & Development · doi:10.1101/gad.8.21.2540 · Cited by 1,215
Innate immune sensing of cytosolic chromatin fragments through cGAS promotes senescence
Glück, S., Guey, B., Gulen, M. F., Wolter, K., Kang, T.-W., Schmacke, N. A., Bridgeman, A., Rehwinkel, J., Zender, L., & Ablasser, A. (2017) · Nature Cell Biology · doi:10.1038/ncb3586 · Cited by 1,196
MTOR regulates the pro-tumorigenic senescence-associated secretory phenotype by promoting IL1A translation
Laberge, R.-M., Sun, Y., Orjalo, A. V., Patil, C. K., Freund, A., Zhou, L., Curran, S. C., Davalos, A. R., Wilson-Edell, K. A., Liu, S., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3195 · Cited by 1,160
Identification of a novel senolytic agent, navitoclax, targeting the Bcl‐2 family of anti‐apoptotic factors
Zhu, Y., Tchkonia, T., Fuhrmann‐Stroissnigg, H., Dai, H. M., Ling, Y. Y., Stout, M. B., Pirtskhalava, T., Giorgadze, N., Johnson, K. O., Giles, C. B., et al. (2016) · Aging Cell · doi:10.1111/acel.12445 · Cited by 1,148
Treating cancer with selective CDK4/6 inhibitors
O'Leary, B., Finn, R. S., & Turner, N. C. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.26 · Cited by 1,137
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1
Harbour, J. W., Luo, R. X., Santi, A. D., Postigo, A. A., & Dean, D. C. (1999) · Cell · doi:10.1016/s0092-8674(00)81519-6 · Cited by 1,057
Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
Zhang, J., Bu, X., Wang, H., Zhu, Y., Geng, Y., Nihira, N. T., Tan, Y., Ci, Y., Wu, F., Dai, X., et al. (2018) · Nature · doi:10.1038/nature25015 · Cited by 1,013
Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts
Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., & Barrett, J. C. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13742 · Cited by 1,008
A 20s complex containing CDC27 and CDC16 catalyzes the mitosis-specific conjugation of ubiquitin to cyclin B
King, R. W., Peters, J., Tugendreich, S., Rolfe, M., Hieter, P., & Kirschner, M. W. (1995) · Cell · doi:10.1016/0092-8674(95)90338-0 · Cited by 956
p35 is a neural-specific regulatory subunit of cyclin-dependent kinase 5
Tsai, L., Delalle, I., Caviness, V. S., Chae, T. H., & Harlow, E. (1994) · Nature · doi:10.1038/371419a0 · Cited by 923
Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution.Preprint
Lee, M., Reynisdóttir, I., & Massagué, J. (1995) · Genes & Development · doi:10.1101/gad.9.6.639 · Cited by 889
Unmasking senescence: context-dependent effects of SASP in cancer
Faget, D. V., Ren, Q., & Stewart, S. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0156-2 · Cited by 863
Loss of p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis
Sharpless, N. E., Bardeesy, N., Lee, K.-H., Carrasco, D., Castrillon, D. H., Aguirre, A. J., Wu, E. A., Horner, J. W., & DePinho, R. A. (2001) · Nature · doi:10.1038/35092592 · Cited by 848
Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles
Galluzzi, L., Bravo-San Pedro, J. M., Levine, B., Green, D. R., & Kroemer, G. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.22 · Cited by 842
Self-citation
The broken cycle: E2F dysfunction in cancer
Kent, L. N., & Leone, G. W. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0143-7 · Cited by 807
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6
Malumbres, M., Sotillo, R., Santamarı́a, D., Galán, J., Cerezo, A., Ortega, S., Dubus, P., & Barbacid, M. (2004) · Cell · doi:10.1016/j.cell.2004.08.002 · Cited by 793
CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
Deng, J., Wang, E. S., Jenkins, R. W., Li, S., Dries, R., Yates, K., Chhabra, S., Huang, W., Liu, H., Aref, A. R., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0915 · Cited by 770
Non-Cell-Autonomous Tumor Suppression by p53
Lujambio, A., Akkari, L., Simon, J., Grace, D., Tschaharganeh, D. F., Bolden, J. E., Zhao, Z., Thapar, V., Joyce, J. A., Krizhanovsky, V., et al. (2013) · Cell · doi:10.1016/j.cell.2013.03.020 · Cited by 766
Control of Metastasis by NK Cells
López‐Soto, A., Gonzalez, S. R., Smyth, M. J., & Galluzzi, L. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.06.009 · Cited by 744
Self-citation
Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways
Alarcón, C., Zaromytidou, A.-I., Xi, Q., Gao, S., Yu, J., Fujisawa, S., Barlas, A., Miller, A. N., Manova-Todorova, K., Macias, M. J., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.035 · Cited by 719
Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.Preprint
Guan, K., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C., Matera, A. G., & Xiong, Y. (1994) · Genes & Development · doi:10.1101/gad.8.24.2939 · Cited by 707
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in β-islet cell hyperplasia
Rane, S. G., Dubus, P., Mettus, R. V., Galbreath, E. J., Boden, G., Reddy, E. P., & Barbacid, M. (1999) · Nature Genetics · doi:10.1038/8751 · Cited by 700
Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis
Bonapace, L., Coissieux, M., Wyckoff, J. B., Mertz, K. D., Varga, Z., Junt, T., & Bentires‐Alj, M. (2014) · Nature · doi:10.1038/nature13862 · Cited by 698
Transcriptional Landscape of Human Tissue Lymphocytes Unveils Uniqueness of Tumor-Infiltrating T Regulatory Cells
De Simone, M., Arrigoni, A., Rossetti, G., Gruarin, P., Ranzani, V., Politano, C., Bonnal, R. J. P., Provasi, E., Sarnicola, M. L., Panzeri, I., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.021 · Cited by 687
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer
Terme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684
Impact of oncogenic pathways on evasion of antitumour immune responses
Spranger, S., & Gajewski, T. F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.117 · Cited by 675
CCL2-induced chemokine cascade promotes breast cancer metastasis by enhancing retention of metastasis-associated macrophages
Kitamura, T., Qian, B., Soong, D. Y. H., Cassetta, L., Noy, R., Sugano, G., Kato, Y., Li, J., & Pollard, J. W. (2015) · The Journal of Experimental Medicine · doi:10.1084/jem.20141836 · Cited by 659
The Genetic Landscape and Clonal Evolution of Breast Cancer Resistance to Palbociclib plus Fulvestrant in the PALOMA-3 Trial
O’Leary, B., Cutts, R. J., Liu, Y., Hrebien, S., Huang, X., Fenwick, K., André, F., Loibl, S., Loi, S., García-Murillas, I., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0264 · Cited by 657
Mouse development and cell proliferation in the absence of D-cyclins
Kozar, K., Ciemerych, M. A., Rebel, V. I., Shigematsu, H., Zagozdzon, A., Sicinska, E., Geng, Y., Yu, Q., Bhattacharya, S., Bronson, R. T., et al. (2004) · Cell · doi:10.1016/j.cell.2004.07.025 · Cited by 647
Human cyclin E, a new cyclin that interacts with two members of the CDC2 gene family
Koff, A., Cross, F., Fisher, A. L., Schumacher, J. M., Guellec, K. L., Philippe, M., & Roberts, J. M. (1991) · Cell · doi:10.1016/0092-8674(91)90044-y · Cited by 642
Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment
Zhong, Z., Sánchez‐López, E., & Karin, M. (2016) · Cell · doi:10.1016/j.cell.2016.05.051 · Cited by 585
Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
The hallmarks of successful anticancer immunotherapy
Galluzzi, L., Chan, T. A., Kroemer, G., Wolchok, J. D., & López-Soto, A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat7807 · Cited by 575
Self-citation
Linking cellular stress responses to systemic homeostasis
Galluzzi, L., Yamazaki, T., & Kroemer, G. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0068-0 · Cited by 551
Self-citation
A systematic screen for CDK4/6 substrates links FOXM1 phosphorylation to senescence suppression in cancer cells
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others
Sabapathy, K., & Lane, D. P. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.151 · Cited by 517
NF-κB and the Transcriptional Control of Inflammation
Mitchell, J. P., & Carmody, R. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.007 · Cited by 516
Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6
Toogood, P. L., Harvey, P. J., Repine, J. T., Sheehan, D. J., VanderWel, S. N., Zhou, H., Keller, P. R., McNamara, D. J., Sherry, D., Zhu, T., et al. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049354h · Cited by 513
Untitled work
(1995) · PubMed · Cited by 496
Stromal senescence establishes an immunosuppressive microenvironment that drives tumorigenesis
Ruhland, M. K., Loza, A. J., Capietto, A.-H., Luo, X., Knolhoff, B. L., Flanagan, K. C., Belt, B. A., Alspach, E., Leahy, K., Luo, J., et al. (2016) · Nature Communications · doi:10.1038/ncomms11762 · Cited by 496
Evidence that the G1-S and G2-M transitions are controlled by different cdc2 proteins in higher eukaryotes
Fang, F., & Newport, J. W. (1991) · Cell · doi:10.1016/0092-8674(91)90117-h · Cited by 483
The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade
Schaer, D. A., Beckmann, R. P., Dempsey, J. A., Huber, L., Forest, A., Amaladas, N., Li, Y., Wang, Y. C., Rasmussen, E. R., Chin, D., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.02.053 · Cited by 469
Isolation of the human cdk2 gene that encodes the cyclin A- and adenovirus E1A-associated p33 kinase
Tsai, L., Harlow, E., & Meyerson, M. M. (1991) · Nature · doi:10.1038/353174a0 · Cited by 461
Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
Chen, P., Lee, N. V., Hu, W., Xu, M., Ferre, R. A., Lam, H., Bergqvist, S., Solowiej, J., Diehl, W., He, Y.-A., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0300 · Cited by 444
Enhancing Chemotherapy Efficacy in Pten-Deficient Prostate Tumors by Activating the Senescence-Associated Antitumor Immunity
Toso, A., Revandkar, A., Di Mitri, D., Guccini, I., Proietti, M., Sarti, M., Pinton, S., Zhang, J., Kalathur, M., Civenni, G., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.044 · Cited by 418
NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination
Ruscetti, M., Leibold, J., Bott, M. J., Fennell, M., Kulick, A., Salgado, N. R., Chen, C.-C., Ho, Y.-J., Sanchez-Rivera, F. J., Feucht, J., et al. (2018) · Science · doi:10.1126/science.aas9090 · Cited by 415
p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells
Iannello, A., Thompson, T. W., Ardolino, M., Lowe, S. W., & Raulet, D. H. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130783 · Cited by 414
CDK inhibitors p18INK4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesisPreprint
Franklin, D. S., Godfrey, V., Lee, H., Kovalev, G. I., Schoonhoven, R., Chen-Kiang, S., Su, L., & Xiong, Y. (1998) · Genes & Development · doi:10.1101/gad.12.18.2899 · Cited by 409
Self-citation
Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer
Condorelli, R., Spring, L. M., O’Shaughnessy, J., Lacroix, L., Bailleux, C., Scott, V., Dubois, J. S., Nagy, R. J., Lanman, R. B., Iafrate, A. J., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx784 · Cited by 407
Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer
Di Mitri, D., Toso, A., Chen, J. J., Sarti, M., Pinton, S., Jost, T. R., D’Antuono, R., Montani, E., Garcia-Escudero, R., Guccini, I., et al. (2014) · Nature · doi:10.1038/nature13638 · Cited by 388
CDK4/6 Inhibitors: The Mechanism of Action May Not Be as Simple as Once Thought
Klein, M. E., Kovatcheva, M., Davis, L. E., Tap, W. D., & Koff, A. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.03.023 · Cited by 378
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival
Wang, H., Nicolay, B. N., Chick, J. M., Gao, X., Geng, Y., Ren, H., Gao, H., Yang, G., Williams, J. A., Suski, J. M., et al. (2017) · Nature · doi:10.1038/nature22797 · Cited by 347
A versatile drug delivery system targeting senescent cells
Muñoz‐Espín, D., Rovira, M., Galiana, I., Giménez, C., Lozano‐Torres, B., Paez‐Ribes, M., Llanos, S., Chaib, S., Muñoz‐Martín, M., Ucero, A. C., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809355 · Cited by 339
Requirement for cyclin D3 in lymphocyte development and T cell leukemias
Sicińska, E., Aifantis, I., Cam, L. L., Swat, W., Borowski, C., Yu, Q., Ferrando, A. A., Levin, S. D., Geng, Y., von Boehmer, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00301-5 · Cited by 338
A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis
Kollmann, K., Heller, G., Schneckenleithner, C., Warsch, W., Scheicher, R., Ott, R. G., Schäfer, M., Fajmann, S., Schlederer, M., Schiefer, A.-I., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.07.012 · Cited by 313
Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302
Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma
Leonard, J. P., LaCasce, A. S., Smith, M. R., Noy, A., Chirieac, L. R., Rodig, S. J., Yu, J. Q., Vallabhajosula, S., Schoder, H., English, P., et al. (2012) · Blood · doi:10.1182/blood-2011-10-388298 · Cited by 299
Self-citation
CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
Vijayaraghavan, S., Karakaş, C., Doostan, I., Chen, X., Bui, T. N., Yi, M., Raghavendra, A. S., Zhao, Y., Bashour, S. I., Ibrahim, N. K., et al. (2017) · Nature Communications · doi:10.1038/ncomms15916 · Cited by 299
CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response
Bancerek, J., Poss, Z. C., Steinparzer, I., Sedlyarov, V., Pfaffenwimmer, T., Mikulic, I., Dölken, L., Strobl, B., Müller, M., Taatjes, D. J., et al. (2013) · Immunity · doi:10.1016/j.immuni.2012.10.017 · Cited by 297
Chemotherapy induced DNA damage response: Convergence of drugs and pathways
Woods, D., & Turchi, J. J. (2013) · Cancer Biology & Therapy · doi:10.4161/cbt.23761 · Cited by 296
The autophagic network and cancer
Rybstein, M. D., Pedro, J. M. B., Kroemer, G., & Galluzzi, L. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0042-2 · Cited by 294
Self-citation
Oncogene-induced senescence and tumour control in complex biological systems
Galluzzi, L., & Vitale, I. (2018) · Cell Death and Differentiation · doi:10.1038/s41418-018-0102-y · Cited by 286
Self-citation
Cell-Cycle Proteins Control Production of Neutrophil Extracellular Traps
Amulic, B., Knackstedt, S. L., Abed, U. A., Deigendesch, N., Harbort, C. J., Caffrey, B. E., Brinkmann, V., Heppner, F. L., Hinds, P. W., & Zychlinsky, A. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.10.013 · Cited by 274
Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression
Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., et al. (2018) · Molecular Cell · doi:10.1016/j.molcel.2018.10.034 · Cited by 265
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1.
Bates, S., Bonetta, L. P., MacAllan, D., Parry, D., Holder, A. A., Dickson, C., & Peters, G. (1994) · PubMed · Cited by 260
Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer
Formenti, S. C., Lee, P. P., Adams, S., Goldberg, J. D., Li, X., Xie, M. W., Ratikan, J. A., Felix, C., Hwang, L. H., Faull, K. F., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3322 · Cited by 260
Self-citation
Macrophages
Guerriero, J. L. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.07.001 · Cited by 255
p27kip1 functions as an anergy factor inhibiting interleukin 2 transcription and clonal expansion of alloreactive human and mouse helper T lymphocytes
Boussiotis, V. A., Freeman, G. J., Taylor, P. A., Berezovskaya, A., Grass, I., Blazar, B. R., & Nadler, L. M. (2000) · Nature Medicine · doi:10.1038/73144 · Cited by 231
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6
Baughn, L. B., Di Liberto, M., Wu, K., Toogood, P. L., Louie, T., Gottschalk, R., Niesvizky, R., Cho, H., Ely, S., Moore, M. A. S., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1098 · Cited by 225
Self-citation
Human NK Cells Are Alerted to Induction of p53 in Cancer Cells by Upregulation of the NKG2D Ligands ULBP1 and ULBP2
Textor, S., Fiegler, N., Arnold, A., Porgador, A., Hofmann, T. G., & Cerwenka, A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-3211 · Cited by 221
CDK7 Inhibition Potentiates Genome Instability Triggering Anti-tumor Immunity in Small Cell Lung Cancer
Zhang, H., Christensen, C. L., Dries, R., Oser, M. G., Deng, J., Diskin, B., Li, F., Pan, Y., Zhang, X., Yin, Y., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.11.003 · Cited by 220
Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice
McCartney, A., Migliaccio, I., Bonechi, M., Biagioni, C., Romagnoli, D., Luca, F. D., Galardi, F., Risi, E., Santo, I. D., Benelli, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00666 · Cited by 195
Pharmacological modulation of nucleic acid sensors - therapeutic potential and persisting obstacles
Vanpouille-Box, C., Hoffmann, J. A., & Galluzzi, L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0043-2 · Cited by 183
Self-citation
Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor–positive Breast Cancer
Michaloglou, C., Crafter, C., Siersbæk, R., Delpuech, O., Curwen, J., Carnevalli, L. S., Staniszewska, A. D., Polanska, U. M., Cheraghchi-Bashi, A., Lawson, M., et al. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0537 · Cited by 182
The epigenetic regulator Uhrf1 facilitates the proliferation and maturation of colonic regulatory T cells
Obata, Y., Furusawa, Y., Endo, T. A., Sharif, J., Takahashi, D., Atarashi, K., Nakayama, M., Onawa, S., Fujimura, Y., Takahashi, M., et al. (2014) · Nature Immunology · doi:10.1038/ni.2886 · Cited by 179
NFATc2-Mediated Repression of Cyclin-Dependent Kinase 4 Expression
Baksh, S., Widlund, H. R., Frazer‐Abel, A. A., Du, J., Fosmire, S. P., Fisher, D. E., DeCaprio, J. A., Modiano, J. F., & Burakoff, S. J. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00701-3 · Cited by 172
CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1
Liu, T., Yu, J., Deng, M., Yin, Y., Zhang, H., Luo, K., Qin, B., Li, Y., Wu, C., Ren, T., et al. (2017) · Nature Communications · doi:10.1038/ncomms13923 · Cited by 164
Induction of therapeutic senescence in vemurafenib-resistant melanoma by extended inhibition of CDK4/6
Yoshida, A., Lee, E. K., & Diehl, J. A. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2931 · Cited by 153
MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
Cornell, L., Wander, S. A., Visal, T. H., Wagle, N., & Shapiro, G. I. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.02.023 · Cited by 141
Tumor-Infiltrating Regulatory T Cells: Phenotype, Role, Mechanism of Expansion In Situ and Clinical Significance
Tanchot, C., Terme, M., Pere, H., Tran, T., Benhamouda, N., Strioga, M., Banissi, C., Galluzzi, L., Kroemer, G., & Tartour, E. (2013) · Cancer Microenvironment · doi:10.1007/s12307-012-0122-y · Cited by 138
Self-citation
Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development
Solvason, N. W., Wu, W. W., Parry, D., Mahony, D., Lam, E. W. ‐., Glassford, J., Klaus, G. G. B., Siciński, P., Weinberg, R. A., Liu, Y.-J., et al. (2000) · International Immunology · doi:10.1093/intimm/12.5.631 · Cited by 135
A unique function for cyclin D3 in early B cell development
Cooper, A. B., Sawai, C. M., Sicińska, E., Powers, S. E., Siciński, P., Clark, M. R., & Aifantis, I. (2006) · Nature Immunology · doi:10.1038/ni1324 · Cited by 126
Type I interferons and dendritic cells in cancer immunotherapy
(2019) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2019.06.001 · Cited by 124
MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
Vilgelm, A. E., Saleh, N., Shattuck-Brandt, R. L., Riemenschneider, K., Slesur, L., Chen, S., Johnson, C. A., Yang, J., Blevins, A., Yan, C. W., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav7171 · Cited by 123
CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells.
Tourigny, M., Ursini-Siegel, J., Lee, H., Toellner, K., Cunningham, A., Franklin, D., Ely, S., Chen, M., Qin, X.-F. F., Xiong, Y., et al. (2002) · Immunity · doi:10.1016/s1074-7613(02)00364-3 · Cited by 121
Self-citation
A Requirement for Cyclin-Dependent Kinase 6 in Thymocyte Development and Tumorigenesis
Hu, M. G., Deshpande, A., Enos, M., Mao, D., Hinds, E. A., Hu, G., Chang, R., Guo, Z., Dose, M., Mao, C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2473 · Cited by 116
Foxp3 Protein Stability Is Regulated by Cyclin-dependent Kinase 2*
Morawski, P. A., Mehra, P., Chen, C., Bhatti, T. R., & Wells, A. D. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.467704 · Cited by 114
Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
Laroche-Clary, A., Chaire, V., Algeo, M.-P., Derieppe, M.-A., Loarer, F. L., & Italiano, A. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0482-3 · Cited by 111
Stromal Senescence By Prolonged CDK4/6 Inhibition Potentiates Tumor Growth
Guan, X., LaPak, K. M., Hennessey, R. C., Yu, C. Y., Shakya, R., Zhang, J., & Burd, C. E. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0319 · Cited by 108
Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies
Niu, Y., Xu, J., & Sun, T. (2019) · Journal of Cancer · doi:10.7150/jca.32628 · Cited by 102
PD-L1 is expressed on human platelets and is affected by immune checkpoint therapy
Rolfes, V., Idel, C., Pries, R., Plötze‐Martin, K., Habermann, J. K., Gemoll, T., Bohnet, S., Latz, E., Ribbat‐Idel, J., Franklin, B. S., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25446 · Cited by 97
Lysosomal trapping of palbociclib and its functional implications
Llanos, S., Megias, D., Blanco-Aparicio, C., Hernández-Encinas, E., Rovira, M., Pietrocola, F., & Serrano, M. (2019) · Oncogene · doi:10.1038/s41388-019-0695-8 · Cited by 96
Connecting the dots: therapy-induced senescence and a tumor-suppressive immune microenvironment
Vilgelm, A. E., Johnson, C. A., Prasad, N., Yang, J., Chen, S.-C., Ayers, G. D., Pawlikowski, J. S., Raman, D., Sosman, J. A., Kelley, M., et al. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv406 · Cited by 95
Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy
Vitale, I., Sistigu, A., Manic, G., Rudqvist, N.-P., Trajanoski, Z., & Galluzzi, L. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.01.003 · Cited by 95
Self-citation
Molecular and in vivo Functions of the CDK8 and CDK19 Kinase Modules
Dannappel, M., Sooraj, D., Loh, J. J., & Firestein, R. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00171 · Cited by 90
ATRX is a regulator of therapy induced senescence in human cells
Kovatcheva, M., Liao, W., Klein, M. E., Robine, N., Geiger, H., Crago, A. M., Dickson, M. A., Tap, W. D., Singer, S., & Koff, A. (2017) · Nature Communications · doi:10.1038/s41467-017-00540-5 · Cited by 89
Modeling Tumor Immunology and Immunotherapy in Mice
Buqué, A., & Galluzzi, L. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.07.003 · Cited by 88
Self-citation
CDK6 kinase activity is required for thymocyte development
Hu, M. G., Deshpande, A., Schlichting, N., Hinds, E. A., Mao, C., Dose, M., Hu, G., Etten, R. A. V., Gounari, F., & Hinds, P. W. (2011) · Blood · doi:10.1182/blood-2010-08-300517 · Cited by 84
CDK5: A Unique CDK and Its Multiple Roles in the Nervous System
Cortés, N., Guzmán‐Martínez, L., Andrade, V., González, A., & Maccioni, R. B. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180792 · Cited by 82
Cyclin D3 Is Selectively Required for Proliferative Expansion of Germinal Center B Cells
Cato, M. H., Chintalapati, S. K., Yau, I. W., Omori, S. A., & Rickert, R. C. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.00650-10 · Cited by 80
Deregulation of Retroelements as an Emerging Therapeutic Opportunity in Cancer
Ishak, C. A., Classon, M., & Carvalho, D. D. D. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.05.008 · Cited by 79
New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation
Wells, A. D., & Morawski, P. A. (2014) · Nature reviews. Immunology · doi:10.1038/nri3625 · Cited by 78
Cyclin-Dependent Kinase 2 Controls Peripheral Immune Tolerance
Chunder, N., Wang, L., Chen, C., Hancock, W. W., & Wells, A. D. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1202313 · Cited by 75
Cyclin-dependent kinase 5 activity is required for T cell activation and induction of experimental autoimmune encephalomyelitis
Pareek, T. K., Lam, E., Zheng, X., Askew, D., Kulkarni, A. B., Chance, M. R., Huang, A. Y.-C., Cooke, K. R., & Letterio, J. J. (2010) · The Journal of Experimental Medicine · doi:10.1084/jem.20100876 · Cited by 75
Small-molecule studies identify CDK8 as a regulator of IL-10 in myeloid cells
Johannessen, L. H., Sundberg, T. B., O'Connell, D. J., Kolde, R., Berstler, J., Billings, K., Khor, B., Seashore-Ludlow, B. A., Fassl, A., Russell, C. N., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2458 · Cited by 73
CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation
Lopez-Mejia, I. C., Lagarrigue, S., Giralt, A., Martinez-Carreres, L., Zanou, N., Denechaud, P.-D., Castillo-Armengol, J., Chavey, C., Orpinell, M., Delacuisine, B., et al. (2017) · Molecular Cell · doi:10.1016/j.molcel.2017.09.034 · Cited by 71
Immunomodulatory Roles of Cell Cycle Regulators
Laphanuwat, P., & Jirawatnotai, S. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00023 · Cited by 71
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
Acevedo, M., Vernier, M., Mignacca, L., Lessard, F., Huot, G., Moiseeva, O. V., Bourdeau, V., & Ferbeyre, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2347 · Cited by 70
Cloning and characterization of murine p16INK4a and p15INK4b genes.
Quelle, D. E., Ashmun, R. A., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., & Serrano, M. (1995) · PubMed · Cited by 69
Characterization of cytokine differential induction of STAT complexes in primary human T and NK cells
Yu, C., Young, H. A., & Ortaldo, J. (1998) · Journal of Leukocyte Biology · doi:10.1002/jlb.64.2.245 · Cited by 69
Cyclin-dependent kinase activity is required for type I interferon production
Cingöz, O., & Goff, S. P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1720431115 · Cited by 68
Requirement for cyclin D3 in germinal center formation and function
Peled, J. U., Yu, J. J., Jeganathan, V., Bi, E., Ding, B. B., Krupski, M., Shaknovich, R., Siciński, P., Diamond, B., Scharff, M. D., et al. (2010) · Cell Research · doi:10.1038/cr.2010.55 · Cited by 67
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK 4/6‐independent manner
Hsieh, F., Chen, Y., Hung, M., Chu, P., Tsai, M., Chen, L., Hsiao, Y., Shih, C., Chang, M.-J., Chao, T., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12072 · Cited by 66
To Cycle or Fight—CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity
Ameratunga, M., Kipps, E., Okines, A. F. C., & Lopez, J. S. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1999 · Cited by 61
Molecular Cloning, Expression Pattern, and Chromosomal Localization of Human CDKN2D/INK4d,an Inhibitor of Cyclin D-Dependent Kinases
Okuda, T., Hirai, H., Valentine, V. A., Shurtleff, S. A., Kidd, V. J., Lahti, J. M., Sherr, C. J., & Downing, J. R. (1995) · Genomics · doi:10.1006/geno.1995.9957 · Cited by 57
Inhibition of Cdk8/Cdk19 Activity Promotes Treg Cell Differentiation and Suppresses Autoimmune Diseases
Guo, Z., Wang, G., Lv, Y., Wan, Y. Y., & Zheng, J. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01988 · Cited by 54
NK Cell–Specific CDK8 Deletion Enhances Antitumor Responses
Witalisz-Siepracka, A., Gotthardt, D., Prchal-Murphy, M., Didara, Z., Menzl, I., Prinz, D., Edlinger, L., Putz, E. M., & Sexl, V. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0183 · Cited by 47
SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
Yoshida, A., Bu, Y., Qie, S., Wrangle, J. M., Camp, E. R., Hazard, E. S., Hardiman, G., de Leeuw, R., Knudsen, K. E., & Diehl, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aax6352 · Cited by 46
Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes
Sicinska, E., Lee, Y.-M., Gits, J., Shigematsu, H., Yu, Q., Rebel, V. I., Geng, Y., Marshall, C. J., Akashi, K., Dorfman, D. M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-06 · Cited by 45
Interplay between dendritic cells and cancer cells
Martínek, J., Wu, T.-C., Cadena, D., Banchereau, J., & Palucka, K. (2019) · International review of cytology · doi:10.1016/bs.ircmb.2019.07.008 · Cited by 45
CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival
Martínez-Carreres, L., Puyal, J., Leal-Esteban, L. C., Orpinell, M., Castillo-Armengol, J., Giralt, A., Dergai, O., Moret, C., Barquissau, V., Nasrallah, A., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0708 · Cited by 43
Cyclin-dependent kinase 5 represses Foxp3 gene expression and Treg development through specific phosphorylation of Stat3 at Serine 727
Lam, E., Choi, S. H., Pareek, T. K., Kim, B.-G., & Letterio, J. J. (2015) · Molecular Immunology · doi:10.1016/j.molimm.2015.06.015 · Cited by 32
CDK-Mediated Regulation of Cell Functions via c-Jun Phosphorylation and AP-1 Activation
Bush, T. J. V., & Bishop, G. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019468 · Cited by 32
The Cyclin-Dependent Kinase Inhibitor p27kip1 Is Required for Transplantation Tolerance Induced by Costimulatory Blockade
Rowell, E. A., Wang, L., Hancock, W. W., & Wells, A. D. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.8.5169 · Cited by 31
Platelet Metabolism and Other Targeted Drugs; Potential Impact on Immunotherapy
Marie, P. K., Lam, M. S., Sorokin, A. V., Overman, M. J., Kopetz, S., & Menter, D. G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00107 · Cited by 29
SASP-Dependent Interactions between Senescent Cells and Platelets Modulate Migration and Invasion of Cancer Cells
Valenzuela, C. A., Quintanilla, R., Olate‐Briones, A., Venturini, W., Mancilla, D., Cayo, Á., Moore‐Carrasco, R., & Brown, N. E. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20215292 · Cited by 29
Cdk5 controls IL-2 gene expression via repression of the mSin3a-HDAC complex
Lam, E., Pareek, T. K., & Letterio, J. J. (2015) · Cell Cycle · doi:10.4161/15384101.2014.987621 · Cited by 23
Cyclin-dependent kinase 5 activity is required for allogeneic T-cell responses after hematopoietic cell transplantation in mice
Askew, D., Pareek, T. K., Eid, S. K., Ganguly, S., Tyler, M., Huang, A. Y.-C., Letterio, J. J., & Cooke, K. R. (2016) · Blood · doi:10.1182/blood-2016-05-702738 · Cited by 21
First Insight into the Kinome of Human Regulatory T Cells
König, S., Probst‐Kepper, M., Reinl, T., Jeron, A., Huehn, J., Schraven, B. L., & Jänsch, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040896 · Cited by 16
T‐cell intrinsic and extrinsic mechanisms of p27Kip1 in the regulation of CD8 T‐cell memory
Jatzek, A., Tejera, M. M., Plisch, E. H., Fero, M. L., & Suresh, M. (2012) · Immunology and Cell Biology · doi:10.1038/icb.2012.71 · Cited by 13
Regulation of T Cell Differentiation and Alloimmunity by the Cyclin-Dependent Kinase Inhibitor p18ink4c
Rowell, E. A., Wang, L., Chunder, N., Hancock, W. W., & Wells, A. D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0091587 · Cited by 10

Sorted by citations

Immunogenic cell stress and death
Kroemer, G., Galassi, C., Zitvogel, L., & Galluzzi, L. (2022) · Nature Immunology · doi:10.1038/s41590-022-01132-2 · Cited by 1,353
Self-citation
Targeting immunogenic cell stress and death for cancer therapy
Galluzzi, L., Guilbaud, E., Schmidt, D. R., Kroemer, G., & Marincola, F. M. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00920-9 · Cited by 606
Self-citation
Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics
Yamaguchi, H., Hsu, J.-M., Yang, W., & Hung, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00601-9 · Cited by 512
Emerging evidence for adapting radiotherapy to immunotherapy
Galluzzi, L., Aryankalayil, M. J., Coleman, C. N., & Formenti, S. C. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00782-x · Cited by 389
Self-citation
Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer
Petroni, G., Cantley, L. C., Santambrogio, L., Formenti, S. C., & Galluzzi, L. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00579-w · Cited by 218
Self-citation

See all 163

Authors: Petroni, G., Formenti, S. C., Chen-Kiang, S., & Galluzzi, L.
Affiliations: Weill Cornell Medicine (US)
Université Paris Cité (FR)
Corresponding author: Galluzzi, Lorenzo
ORCID: Petroni, Giulia
Formenti, Silvia C.
Galluzzi, Lorenzo
Venue: Nature Reviews Immunology
Publisher: Springer Science and Business Media LLC
Published: 2020-04-28
Volume: 20
Issue: 11
Pages: 669-679
ISSN: 1474-1733 (ISSN-L)
1474-1741
DOI: 10.1038/s41577-020-0300-y
PMC: PMC7584736
OpenAlex: W3020753817
Cited by: 163
References: 161
Citations by year: 2026: 17 · 2025: 22 · 2024: 22 · 2023: 26 · 2022: 45 · 2021: 20 · 2020: 11
FWCI: 2.74
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature reviews. Immunology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Florence Research (University of Florence) (submittedVersion)
Funders: National Cancer Institute (R01CA188794, P01CA214274)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords: CDK4/6 inhibitors, immunomodulation, antitumor immunity, cell cycle inhibitors, palbociclib, abemaciclib, ribociclib, breast cancer, cyclin-dependent kinases, tumor immunology
MeSH terms: Antineoplastic Agents, Immunological, Animals, Cell Cycle, Clinical Trials as Topic, Humans, Neoplasms, Cell Cycle Proteins, Protein Kinase Inhibitors, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunomodulation by anticancer cell cycle inhibitors

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks